No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [Myocardial Infarction]

Conclusions—
Ticagrelor pretreatment versus ticagrelor given in the catheterization laboratory in patients with ST-segment–elevation myocardial infarction undergoing primary PCI did not improve the composite end point of all-cause mortality or MI or stent thrombosis or its individual components at 30 days.

Source: Circulation: Cardiovascular Interventions - March 16, 2018 Category: Cardiology Authors: Koul, S., Smith, J. G., Gotberg, M., Omerovic, E., Alfredsson, J., Venetsanos, D., Persson, J., Jensen, J., Lagerqvist, B., Redfors, B., James, S., Erlinge, D. Tags: Anticoagulants, Percutaneous Coronary Intervention, Treatment Myocardial Infarction Source Type: research